Piper Jaffray analyst Danielle Brill raised her price target for GW Pharmaceuticals to $210 from $185 after Epidiolex sales in Q1 of $33.5M “solidly beat” her $20.7M estimate. Epidiolex’s growth trajectory will continue over the coming quarters given expected launch in Europe, ongoing dose-titrations, increasing penetration into adult population, transition of remaining expanded access program patients to commercial product, and expansion into new indications, Brill tells investors in a research note. She expects GW’s momentum to continue and reiterates an Overweight rating on the shares.
Tuesday, May 7, 2019
Haemonetics reports Q4 adj. EPS 61c, consensus 55c
Reports Q4 revenue $249.3M, consensus $250.63M. Chris Simon, Haemonetics’ CEO, said: “We are pleased with our strong finish to Fiscal 2019. We launched NexSys, the platform we believe is best positioned to support plasma industry growth. We also continued to reduce complexity and costs to meaningfully expand our profit margins, while freeing up resources to invest in growth. Our positive results are evidence that our strategy is sound and creating momentum for additional revenue and profitability growth in Fiscal 2020 as we drive our corporate-wide transformation.”
Mallinckrodt, CPP announce CPP FAP-310 trial did not meet primary endpoint
Cancer Prevention Pharmaceuticals, or CPP, and its partner Mallinckrodt announced that CPP’s pivotal phase 3 clinical trial, CPP FAP-310, of the investigational drug CPP-1X/sulindac in patients with familial adenomatous polyposis, or FAP, did not meet its primary endpoint. Specifically, the reduction of time to the first occurrence of an FAP-related event for the combination of CPP-1X and sulindac did not reach statistical significance compared to the two control arms. CPP FAP-310 included only active comparator arms and was the largest and longest study ever conducted in patients with FAP. Based on the topline results, Mallinckrodt does not plan to pursue the commercialization of the CPP-1X/sulindac program.
Subscribe to:
Posts (Atom)